1. Home
  2. GDTC vs IDAI Comparison

GDTC vs IDAI Comparison

Compare GDTC & IDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

HOLD

Current Price

$0.97

Market Cap

12.4M

Sector

Health Care

ML Signal

HOLD

Logo T Stamp Inc.

IDAI

T Stamp Inc.

N/A

Current Price

$2.46

Market Cap

12.9M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
GDTC
IDAI
Founded
2018
2016
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
12.4M
12.9M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
GDTC
IDAI
Price
$0.97
$2.46
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
5.2K
32.8K
Earning Date
04-24-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
76.50
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$103.06
Revenue Next Year
N/A
$140.06
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$1.80
52 Week High
$3.68
$5.28

Technical Indicators

Market Signals
Indicator
GDTC
IDAI
Relative Strength Index (RSI) 44.84 47.11
Support Level $0.88 $2.31
Resistance Level $1.06 $2.80
Average True Range (ATR) 0.04 0.15
MACD -0.00 -0.00
Stochastic Oscillator 58.33 28.78

Price Performance

Historical Comparison
GDTC
IDAI

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

About IDAI T Stamp Inc.

T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.

Share on Social Networks: